A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant (Sargeant JA), Joseph Henson (Henson J), James Adam King (King JA), Thomas Yates (Yates T), Kamlesh Khunti (Khunti K), Melanie Jane Davies (Davies MJ)
Endocrinol Metab. 2019;34(3):247-262.   Published online 2019 Sep 26     DOI: https://doi.org/10.3803/EnM.2019.34.3.247
Citations to this article as recorded by Crossref logo
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
Expert Opinion on Pharmacotherapy.2021; : 1.     CrossRef
Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. Roux
Obesity.2021; 29(3): 529.     CrossRef
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
BMJ Open.2021; 11(4): e045844.     CrossRef
Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
Cancer Prevention Research.2021; 14(5): 509.     CrossRef
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
Nutrients.2020; 12(2): 510.     CrossRef
GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
Aging Cell.2020;[Epub]     CrossRef